Shares of Absci Corp shifted sharply higher Monday, trading at $6.75 in pre-market — up 5.5% — as dip-buyers stepped in after last week's whiplash. The AI-driven drug discovery company swung from $5.94 to a four-year high of $7.34 and back to $6.40 in just three sessions, all triggered by a single analyst note. For a company burning cash with virtually no revenue, the question now is whether the stock's wild ride reflects genuine conviction or speculative froth.
A Single Analyst Call Moved the Stock Nearly 24% in One Day
On June 4, Leerink Partners initiated coverage of Absci with an Outperform rating and a $12 price target — sending shares to their highest level in over four years. That target sits 78% above Monday's pre-market price, signaling Leerink sees transformative upside in Absci's lead drug candidate, which targets hair loss and endometriosis. Truist Securities recently raised its own target from $9 to $11 , adding to the bullish chorus. But the next-day selloff — a 12.8% drop on June 5 — shows how quickly sentiment can reverse in a thinly traded small-cap.
The Company Has Almost No Revenue and Is Burning $26 Million a Quarter
Absci posted Q1 2026 revenue of just $215,000, far below the $1.43 million forecast.
Cash burn is heavy at roughly $26.3 million per quarter, though the balance sheet is clean: about $126 million in cash with negligible debt.
That runway is projected to last into the first half of 2028 , giving management roughly two years before it likely needs to raise more money — potentially diluting existing shareholders.
Everything Hinges on One Drug Candidate's Trial Data This Year
A Phase 2 trial for endometriosis is set for Q4 2026, with interim hair-loss results also expected this year.
BTIG projects up to $2.2 billion in peak sales for the lead candidate , a staggering figure for a company with a market cap under $1 billion. CEO Sean McClain has called 2026 "a data-rich year" with "multiple readouts ahead." Positive data could justify the stock's valuation many times over; a stumble could crater it.
Insider Buying Adds a Small Vote of Confidence
Insiders purchased roughly $430,000 in stock over the past three months with no reported selling — a modest but notable signal. The broader consensus from nine analysts is Strong Buy, with nine recommending purchase and just one holding. Yet the price-to-sales ratio exceeds 558 times , a reminder that at today's prices, investors are paying for a future that hasn't arrived.